Large cell anaplastic medulloblastoma metastatic to the scalp: Tumor and derived stem-like cells features

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Mastronuzzi, Angela ^a   Miele, Evelina ^b,c   Po, Agnese ^b   Antonelli, Manila ^d   Buttarelli, Francesca R ^d   Colafati, Giovanna S ^a   del Bufalo, Francesca ^a   Faedda, Roberta ^b   Spinelli, Gian P ^d   Carai, Andrea ^a   Giangaspero, Felice ^d,e   Gulino, Alberto ^b,c   Locatelli, Franco ^a   Ferretti, Elisabetta ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Medulloblastoma; Molecular features; Stem like cells; Subcutaneous metastasis

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; IFOSFAMIDE; TOPOTECAN;

ANGIOGENESIS; ARTICLE; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER CHEMOTHERAPY; CASE REPORT; CELL INVASION; CHILD; CYTOREDUCTIVE SURGERY; DEATH; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL ANAPLASTIC MEDULLOBLASTOMA; MALE; MEDULLOBLASTOMA; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCALP TUMOR; SKIN METASTASIS; STEM CELL; STEM LIKE CELL; TUMOR CELL; TUMOR CLASSIFICATION; CANCER STEM CELL; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; PROGNOSIS;

CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROGNOSIS;

EID: 84899933474     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-262     Document Type: Article

References (40)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012, 14(Suppl 5):v1-v49. 10.1093/neuonc/nos218, 3480240, 23095881.
2. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010, 28(8):1345-1350. 10.1200/JCO.2009.23.5952, 20142599.
3. von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, Rutkowski S. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatr Blood Cancer 2010, 54(3):369-376. 10.1002/pbc.22339, 19908297.
4. Mazloom A, Zangeneh AH, Paulino AC. Prognostic factors after extraneural metastasis of medulloblastoma. Int J Radiat Oncol Biol Phys 2010, 78(1):72-78. 10.1016/j.ijrobp.2009.07.1729, 20133080.
5. Galarza M, Sosa FP. Pure subcutaneous seeding from medulloblastoma. Pediatr Neurol 2003, 29(3):245-249. 10.1016/S0887-8994(03)00215-7, 14629911.
6. Maiti T, Sabharwal P, Pandey P, Devi BI. Subcutaneous metastasis in medulloblastoma: A case report and review of literature. J Pediatr Neurosci 2013, 8(2):168-170. 10.4103/1817-1745.117861, 3783732, 24082943.
7. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012, 8(6):340-351. 10.1038/nrneurol.2012.78, 22565209.
8. Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012, 12(12):818-834. 10.1038/nrc3410, 3889646, 23175120.
9. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488(7409):100-105. 10.1038/nature11284, 3662966, 22832583.
10. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, Ross MG, Russ C, Shefler E, Sivachenko A, Sogoloff B, Stojanov P, Tamayo P, Mesirov JP, Amani V, Teider N, Sengupta S, Francois JP, Northcott PA, Taylor MD, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012, 488(7409):106-110. 10.1038/nature11329, 3413789, 22820256.
11. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011, 29(11):1424-1430. 10.1200/JCO.2010.28.5148, 3082983, 21098324.
12. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stutz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012, 488(7409):49-56. 10.1038/nature11327, 3683624, 22832581.
13. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011, 29(11):1408-1414. 10.1200/JCO.2009.27.4324, 20823417.
14. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012, 123(4):465-472. 10.1007/s00401-011-0922-z, 3306779, 22134537.
15. Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, Coni S, Di Marcotullio L, Biffoni M, Massimi L, Di Rocco C, Screpanti I, Gulino A. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J 2010, 29(15):2646-2658. 10.1038/emboj.2010.131, 2928686, 20581804.
16. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I, Gulino A. MicroRNA profiling in human medulloblastoma. Int J Cancer 2009, 124(3):568-577. 10.1002/ijc.23948, 18973228.
17. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 2011, 17(7):1883-1894. 10.1158/1078-0432.CCR-10-2210, 3071325, 21325292.
18. Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, Eberhart CG, Dubuc A, Guettouche T, Cardentey Y, Bouffet E, Pomeroy SL, Marra M, Malkin D, Rutka JT, Korshunov A, Pfister S, Taylor MD. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012, 123(4):615-626. 10.1007/s00401-011-0899-7, 3306784, 22057785.
19. Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, Po A, Baldi C, Carissimo G, Antonelli M, Spinelli GP, Capalbo C, Donofrio V, Morra I, Nozza P, Gulino A, Giangaspero F, Ferretti E. High-throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol 2014, 16(2):228-240. 10.1093/neuonc/not215, 3895388, 24305714.
20. Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A, Taylor MD, Foreman NK, Vibhakar R. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer 2012, 131(8):1800-1809. 10.1002/ijc.27455, 3375399, 22287205.
21. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006, 24(25):4202-4208. 10.1200/JCO.2006.06.4980, 16943538.
22. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7(10):813-820. 10.1016/S1470-2045(06)70867-1, 17012043.
23. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109. 10.1007/s00401-007-0243-4, 1929165, 17618441.
24. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000, 89(5):395-402. 10.1002/1097-0215(20000920)89:5<395::AID-IJC1>3.0.CO;2-V, 11008200.
25. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006, 66(2):673-681. 10.1158/0008-5472.CAN-05-1580, 16423996.
26. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002, 126(5):540-544.
27. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002, 12(1):36-44.
28. Woodburn RT, Azzarelli B, Montebello JF, Goss IE. Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 2001, 52(1):57-62. 10.1023/A:1010691330670, 11451203.
29. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009, 27(10):1627-1636. 10.1200/JCO.2008.17.9432, 19255330.
30. Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, Castelo Branco P, Baskin B, Ray PN, Bouffet E, Von Bueren AO, Jones DT, Northcott PA, Kool M, Sturm D, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho BK, Kim SK, Wang KC, Eberhart CG, Fevre Montange M, Fouladi M, French PJ, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013, 31(23):2927-2935. 10.1200/JCO.2012.48.5052, 23835706.
31. Srikantha U, Balasubramaniam A, Santosh V, Somanna S, Bhagavatula ID, Ashwathnarayana CB. Recurrence in medulloblastoma - influence of clinical, histological and immunohistochemical factors. Br J Neurosurg 2010, 24(3):280-288.
32. Remke M, Ramaswamy V, Taylor MD. Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol 2013, 25(6):674-681. 10.1097/CCO.0000000000000008, 24076581.
33. Muoio VM, Shinjo SO, Matushita H, Rosemberg S, Teixeira MJ, Marie SK. Extraneural metastases in medulloblastoma. Arq Neuropsiquiatr 2011, 69(2B):328-331. 10.1590/S0004-282X2011000300012, 21625760.
34. Berger MS, Baumeister B, Geyer JR, Milstein J, Kanev PM, LeRoux PD. The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 1991, 74(6):872-877. 10.3171/jns.1991.74.6.0872, 2033446.
35. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40(5):499-507. 10.1038/ng.127, 2912221, 18443585.
36. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011, 71(5):1772-1780. 10.1158/0008-5472.CAN-10-1735, 3049992, 21169407.
37. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG, Garzia L, Van Meter T, Zagzag D, Jabado N, Schwartzentruber J, Majewski J, Scheetz TE, Pfister SM, Korshunov A, Li XN, Scherer SW, Cho YJ, Akagi K, MacDonald TJ, Koster J, McCabe MG, Sarver AL, Collins VP, Weiss WA, Largaespada DA, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012, 482(7386):529-533. 10.1038/nature10825, 3288636, 22343890.
38. Meco D, Servidei T, Riccardi A, Ferlini C, Cusano G, Zannoni GF, Giangaspero F, Riccardi R. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro Oncol 2009, 11(3):250-259. 10.1215/15228517-2008-095, 2718969, 19033425.
39. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Goldman S, Geyer JR, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol 2013, 114(2):173-179. 10.1007/s11060-013-1166-7, 23836190.
40. Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol 2012, 15(2):149-160. 3548579, 23190500.